Objectives: The goal of our study was to compare the frequency and severity of recovery reactions between ketamine and ketamine-propofol 1:1 admixture ("ketofol").
T he ideal agent for emergency department (ED) procedural sedation does not exist. Propofol has excellent ultrashort sedative properties but carries a potential risk of respiratory or hemodynamic compromise that make this sedative agent sometimes undesirable. Furthermore, its use by ED physicians remains controversial or problematic in numerous countries, [1] [2] [3] [4] [5] [6] especially those where emergency medicine is a young specialty. In these conditions, ED physicians have limited safe and available alternative choices, and for its favorable hemodynamic and respiratory profile, ketamine is a valuable one. However, when used alone for dissociative procedural sedation on adults, ketamine is associated with a 10% to 30% risk of unpleasant recovery, [7] [8] [9] [10] [11] [12] [13] potentially impairing the patient's comfort in a significant way. As this psychological issue of ketamine can also be time-consuming or disturbing for ED physicians, since 1973 7 efforts have been made to improve recoveries. Yet unproven, positive psychology and dream-planning, 14 for example, may be considered sufficient by some physicians, but for others routine benzodiazepine pretreatment is the only way to mitigate this disappointing aspect of dissociative sedation. Recently, a significant reduction in recovery reactions has been showed with midazolam prophylaxis, 11 but as the authors did not mention any severity or eventual clinical interventions required by these psychological adverse events, it has been argued that the clinical significance of these findings may be lower. 9 Propofol and ketamine admixture named "ketofol" is gaining interest because of theoretical advantages. [15] [16] [17] [18] [19] [20] [21] The positive effects of each drug may indeed balance the other product downsides: sympathomimetic effects of ketamine could mitigate propofol-associated hypotension and respiratory depression, and propofol could limit the digestive and psychiatric side effects of ketamine. Compared to propofol, ketofol may have a better safety profile: two recent meta-analyses 22, 23 have pointed out a lower incidence of respiratory depression with ketofol. Ketofol finally may induce a lower incidence of recovery reactions than ketamine, but in the absence of direct comparative studies between these agents for procedural sedations on adults, we still cannot conclude on any superiority of ketofol concerning this specific issue.
Our study intended to determine if procedural sedation with ketofol on adults results in a significant decrease in recovery reactions compared with ketamine. We detailed the nature and importance of these psychological adverse events, as well as the clinical interventions required by these events. We also compared proportions of other expected side effects of each drug (nausea or vomiting, hemodynamic compromise), frequencies of adverse airway or respiratory events, procedural sedations efficacy, and finally the satisfaction of patients and staff alike.
METHODS

Study Design and Setting
We performed a multicentric randomized, double-blind, controlled study conducted in both hospital and prehospital setting. Six French EDs using mobile intensive care units participated. Described elsewhere, 24 these mobile units are staffed by a team of three individuals: a nurse, an emergency medical technician, and an emergency physician. Inside the hospital, a similar three-individuals team was involved (an ED physician, an ED nurse, and a technician) and all procedural sedations were conducted in a dedicated resuscitation room in the ED. The trial was promoted by Nice University Hospital, approved by our institution's ethic committee, and registered in ClinicalTrials.gov (NCT01544725). All participants provided written informed consent.
Population
We enrolled adult patients (>18 years) presenting an orthopedic injury and needing a procedural sedation, as identified by emergency physicians. Patients were excluded if they had an American Society of Anesthesiologists physical status 25 greater than 2; had a known hypersensitivity to either study product; had sustained a thoracic, abdominal, spinal, or head injury; had hemodynamic instability; or were intoxicated or schizophrenic. Pregnant women, prisoners, intravenous (IV) drug users or patients unable to give consent were also excluded. Other exclusion criteria were porphyria and glaucoma. If a patient received opiate analgesia before procedural sedation, a safety period of 20 minutes would be required before any study product could be injected.
Study Protocol
Eligible patients willing to participate were randomized to either ketamine or ketofol using a fixed 1:1 allocation ratio determined by a computer-generated randomization list, maintained in the pharmacy. Small, random block sizes of 4 were used to ensure equal allocation to each treatment arm. Following the allocation list, the pharmacist prepared in advance and dispatched sealed indistinguishable study kits to the six emergency services involved. The content of the sealed study kits was not revealed to study participants and emergency physicians, in order to maintain the double blind. This procedure has been used before, 26, 27 especially in studies involving limited available staff.
Once the participant's consent obtained, the nurse of the emergency team had to stay apart to maintain the patient's and the emergency physician's blinding and then unseal the pharmacy kit and prepare study syringes by following a preparation sheet placed in the kit. Depending on randomization, the nurse (otherwise not involved in any other part of the study) had to prepare two syringes using different dilutions with serum saline: the first 20-mL syringe was transparent and contained 10 mg/mL ketamine (ketamine arm) or 5 mg/mL of ketamine (ketofol arm). The second 20-mL syringe, opaque white, contained 10 mg/mL propofol (ketofol arm) or 10% Intralipid (ketamine arm). This soy-based fat emulsion is an effective physical placebo of propofol. 15 The nurse was told to never reveal the nature of products contained in study syringes and did not participate in any outcome collection or any other part of the study. To assess if the physician's blinding was effective, a question was asked in the data sheet about his feeling on which of the two treatments the patient had received, ketamine or ketofol.
At time zero (t0), patients in the ketamine group received 0.1 mL/kg IV of the transparent syringe (corresponding to 1 mg/kg ketamine) and then 0.1 mL/ kg of the white syringe (containing Intralipid). Patients in ketofol group received at t0 the same IV volumes: 0.1 mL/kg of the transparent syringe (0.5 mg/kg ketamine) and then 0.1 ml/kg of the opaque white syringe (0.5 mg/kg propofol). Each injection was administered over 30 seconds, and every dosing was guided by a standardized, study-specific, weight-based schedule.
At t0 + 4 minutes, the emergency physician had to assess the patient's level of sedation using Ramsay's scale. 28 If sedation was sufficient (Ramsay > 3), the procedure could be initiated (fracture or dislocation reduction in most of the cases). If the attending physician determined that the level of sedation was inadequate (Ramsay ≤ 3), an additional half-dose of each study syringe was injected. The same procedure was used at t0 + 8 minutes (additional half-dose). However, at t0 + 12 minutes, if sedation was still inadequate (Ramsay ≤ 3), the attending physician could administer another unblinded sedative agent at his discretion. In this case, the study would still be pursued to its end and data recorded, to take into account proportions of sedation failures in each arm.
All patients had cardiac, blood pressure, pulse oximeter, and nasal sample end-tidal CO 2 monitors (with continuous waveform display) and were placed under supplemental oxygen (at least 8 L/min, 3 minutes before the start of the procedure) until complete recovery. Vital signs, monitoring data, and depth of sedation were recorded on data sheets separate from the clinical record, starting 1 minute before the procedure and every 5 minutes subsequently.
Measures
Our primary outcome was the proportion of patients experiencing a recovery reaction, defined as the composite of one or more criteria in the following list: confusion, anxiety, unpleasant dreams or hallucinations, agitation, and aggressiveness. Pleasant recovery reactions were not counted as adverse events.
Secondary outcomes were the proportion of patients experiencing hypotension (systolic < 100 mm Hg); emesis (nausea and/or vomiting); or respiratory depression defined as central apnea > 20 seconds, upper airway obstruction (absent ETCO 2 waveform but ventilator effort), hypoxia (oxygen saturation < 92% at any time), or ETCO 2 > 50 mm Hg.
We collected data on possible interventions decided by attending physicians facing adverse events, and consequently categorized each adverse event as mild or severe. For recovery reactions, physicians could choose between simple monitoring, verbal reassurance, temporary physical restraint, and titrated IV midazolam. The last three proposals were used to assess clinical interventions required, whereas the last two defined this outcome as severe. Verbal reassurance was recorded when the patient's recovery reaction needed more than a simple monitoring and required for improvement the provider's words, empathy, and presence, but IV midazolam was not necessary.
For hypotension, physicians had the choice between simple monitoring, IV fluids < 500 mL, IV fluids ≥ 500 mL, ephedrine bolus treatment, and catecholamine treatment. The last three proposals defined this hemodynamic outcome as severe.
For digestive adverse events, physicians could choose between simple monitoring, lateral security position, clomipramine injection, and nasogastric tube. The last two proposals defined this outcome as severe.
For respiratory depression, physicians could either record simple monitoring, increase in oxygen flow, verbal or tactile stimulation, mandibular subluxation, bag-valve-mask, or endotracheal tube. The last two proposals defined this outcome as severe.
The satisfaction of patients and physicians was assessed on 100-mm visual analogic scales. To determine if the physician's blinding was effective, a question was asked in the data sheet about his feeling on which of the two treatments the subject had received, ketamine or ketofol.
Data Analysis
Assuming a baseline incidence of recovery reactions of 20% 7, 9, 11, 12, 14, 19 in the ketamine arm, to detect a 15% or greater difference in our primary outcome between the two groups with chi-square tests, with an alpha of 5 and 80% power, 75 patients per group were required. We analyzed the data using an intention-totreat method for the main outcome. The calculations were performed using MedCalc (MedCalc Statistical Software, version 14.8.1) and Statview software (version 5.0, SAS Institute Inc.). In case of missing data concerning the primary outcome, we applied the worst-case scenario approach: we decided to record the presence of a recovery reaction in the ketofol group and the absence of this adverse event in the ketamine group.
Continuous data were compared using Student's t test and categorical data were analyzed using chi-square tests or Fisher's exact test according to the sample size. The confidence intervals (CIs) of the differences in proportions were calculated using an online calculator accessible at http://vassarstats.net/prop2_ind.html. All the variables associated with the main outcome in a univariable analysis with a p-value of less than 0.20 were included in a multivariable analysis performed with a logistic regression using a backward method. Categorical data are presented as proportions AE 95% CI and continuous data are presented as means AE SD. A p-value of 0.05 was considered as being significant.
RESULTS
A total of 152 patients were recruited across the six study sites, with 76 in the ketofol group and 76 patients in the ketamine group. Patient flow during the study period (May 2, 2012, to December 27, 2015) is shown in Figure 1 . Baseline characteristics were similar between groups ( Table 1) .
The blinding assessment showed that physicians unsuccessfully guessed group assignment for 46% of patients in ketamine group and for 49% of patients in ketofol group.
To reach the targeted level of sedation (Ramsay score > 3), more patients in the ketofol group required two extra-doses of study drugs. The achieved depth of sedation was similar between the two groups ( Table 2) .
Using a per-protocol analysis (i.e excluding the patients with protocol violation), four patients in the ketamine group and eight patients in the ketofol group did not reach the targeted level of sedation (Ramsay score > 3) despite administration of the two allowed extra-doses (p = 0.25). Despite these sedation failures, the procedure could be done anyway for 2 patients in the ketamine group and for 2 patients in the ketofol group. The other patients with sedation failures received other sedative drugs in order to perform the intended procedure (propofol for most of them).
For the primary outcome, we observed significantly less recovery reactions with ketofol compared to ketamine: 22.3% versus 44.7% (difference = 22.4%, 95% CI = 7.4%-36.1%, p < 0.01). According to this 22% absolute reduction, the estimated number needed to treat is five ( Table 3) .
The number of observed recovery reactions per patient was more important in the ketamine group (Table 3) . Recovery reactions requiring clinical interventions (verbal reassurance, temporary physical restraint, or titrated IV midazolam) were more frequent with ketamine than with ketofol: 27.6% versus 14.5% (difference = 13.2%, 95% CI = 0.1%-25.7%; Table 3 )
Using a multivariable analysis with logistic regression including age, sex, ASA score, number of doses administrated, type of procedure, Ramsay score, setting (in-hospital or prehospital) and treatment arm, we found that recovery reactions were independently associated with only 2 factors: treatment arm (p = 0.003), with ketofol as protective, and ASA score (p < 0.05), with an ASA 2 as protective (Table 4) .
For secondary outcomes, the frequency of adverse respiratory or hypotensive episodes was similar between groups (Table 5 ).
The proportion of digestive adverse events (nausea or vomiting) was higher in the ketamine group, 18.4% vs. 5.3% in ketofol arm (difference 13.1%, 95% CI: 3-23.2%).
The severity of these digestive adverse events was mild, since only 2 patients in the ketamine group and only one in the ketofol group required an injection of metoclopramide.
The mean satisfaction of patients, measured on 100 mm visual analogic scales, was similar in both groups (82 vs. 83 mm; difference 1.4 mm, 95% CI: À6 to 8.5 mm), as well as the satisfaction of providers (74 vs. 74 mm; difference 0 mm, 95% CI: À10 to 9 mm).
DISCUSSION
To the best of our knowledge, our trial is the first to directly investigate the theoretical psychological advantage of ketofol over ketamine for procedural sedations in adult patients and to detail the nature and importance of recovery reactions as well as the clinical interventions required by these adverse events. In our prospective, randomized, double-blind, placebo-controlled study, we found that ketofol, compared to ketamine, can reduce by 22% the risk of recovery reactions after procedural sedations on adults (estimated number needed to treat of 5).
The clinical importance of this outcome is likely to be debatable among emergency physicians, as perceptions of recovery reactions vary widely: some clinicians find disturbing this psychodysleptic effect of ketamine on adults, but others consider "dream-planning" or "positive psychology" 14 as sufficient (yet unproven) to mitigate this rarely serious side effect. But even if of mild severity, these psychological adverse events can lead to possibly time-consuming interventions such as bedside presence of providers, verbal reassurance, medications, and/or prolonged monitoring. As we found less clinical and pharmacologic interventions required with ketofol compared to ketamine (difference of about 13%), our data might be of interest to emergency physicians. Patients finally are likely to perceive our results as positive, because representing efforts toward improvement of their psychological experience and comfort during and after ED procedural dissociative sedation.
Even if providers were asked to record only clinically significant and unpleasant recovery reactions, we found that almost 45% of patients in the ketamine group developed this side effect, a proportion higher than previously quoted. 7,9,11,12,14,29 Considering that our study was specifically designed to precisely describe the incidence, nature, and importance of this adverse event, we assume that the threshold of physicians recording this outcome may have been lower than that in other studies designed for other purposes. Furthermore, as the only randomized controlled trial previously performed on the same topic and primary outcome 11 as ours did not specify the nature and severity of the recovery reactions encountered, it seems complicated to compare the proportions found in both studies.
Even if recovery reactions frequency was higher in the ketamine group, patients were highly satisfied in similar proportions as in the ketofol group. As one of our study's secondary objective was to specify the nature and importance of interventions required by recovery reactions, the management of these adverse events was standardized, systematic, and probably efficient.
Other studies on recovery reactions for adult procedural sedations exist, but only one study was controlled. Sener et al. 11 compared in a prospective, randomized, and double-blind fashion 151 adult procedural sedations with ketamine alone or ketamine plus midazolam. Their four groups of 45 patients received successively a first slow (≥2 min) IV injection of 0.03 mg/kg midazolam or placebo, then a second slow (≥2 min) IV injection of 1.5 mg/kg ketamine or placebo, and finally an intramuscular (IM) injection of 4 mg/kg ketamine or placebo. Even if blinding was doubtful and unverified by a group assignment question asked to physicians, the study conclusion was that midazolam pretreatment in combined IV and IM groups determined a 17% absolute reduction of recovery reactions, compared to IV plus IM ketamine alone groups. Because this study did not specify the severity of these reactions and the clinical interventions required, it has been argued 9 that this 17% apparent benefit may have been lower because of possible mild reactions, below clinicians' threshold of clinical importance.
Severity analysis of our primary outcome showed that only a minority of patients in ketamine group had severe recovery reactions, even in the absence of a midazolam "protective" pretreatment. As Green and Krauss 9 argued recently, our data tend to confirm that physicians may excessively fear the psychodysleptic effects of ketamine on adults, and even when midazolam prophylaxis is not used, severe emergence reactions appear far less frequent than believed. Providers should therefore pretreat with midazolam only selected adult patients anticipated to be at higher risk of recovery reactions or should directly prefer ketofol for its better psychological profile and its other theoretical advantages, including a lower incidence of emesis.
We found in our multivariable analysis that recovery reactions were independently associated with only 2 factors, treatment arm and ASA score. Adult patients with ASA score of 1 were more likely to experience a recovery reaction than ASA 2 patients (ASA 3 and more were not included in our study). To the Data are reported as n (%) or percent (95% CI).
best of our knowledge, these findings have never been reported before in literature, and its explanation remains hypothetic. The frequencies of hemodynamic or respiratory compromise between study arms in our trial were similar, but as our study was not designed for this purpose and was limited to patients with ASA 1 and 2 patients, it is possible that differences would be pointed out in more fragile patients.
LIMITATIONS
Criteria used to define our primary composite outcome were of mild severity, never leading to permanent trouble or sequelae. Some physicians could therefore consider these events as of little clinical importance. On the other hand, as recovery reactions with ketamine can be disturbing and lead to clinical or pharmacologic time-consuming interventions, one could argue that efforts trying to mitigate this adverse event and improve patients' comfort as well as physicians' experience remain worthwhile.
It could be argued that out-of-hospital noisy and deleterious environmental conditions could promote more recovery reactions than in-hospital setting and therefore lead to a possible confounding bias in our study. However, the multivariable analysis confirmed that this environmental factor was not independently associated with the incidences of recovery reactions.
Even if every attempt was made to conceal drug allocation, physicians blinding may not have been complete. Two possible indications could suggest allocation arm to ED physician: the different dose of ketamine injected in the first syringe and the absence of sedative in the second syringe in the ketamine group. One could argue that the depth of sedation would be lower at the end of the first syringe in the ketofol group and that the absence of sedative effect in the second syringe would be obvious in the ketamine group. However, as physicians unsuccessfully guessed group assignment for approximately half of patients in both study arms, inappropriate blinding seems unlikely and our results should be conclusive. 
CONCLUSION
Compared with ketamine, ketofol for ED procedural sedations on adults improves patient recovery and comfort by limiting the incidence of psychodysleptic events and unpleasant recoveries, with a 22% absolute reduction in our study (number needed to treat = 5). Nonpharmacologic interventions as well as medications required by these recovery reactions seem also to be less frequent with ketofol. Furthermore, alongside a low incidence of respiratory and hemodynamic events, another advantage of ketofol over ketamine would be its favorable digestive profile, as our study pointed out a threefold reduction of emesis for patients who received ketofol. When propofol deep sedation is not a valuable or available sedative option, ED physicians may therefore prefer to use ketofol rather than ketamine alone for ED procedural sedations on adults.
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